SCHEMBL30723747

SCHEMBL30723747

O=C1CCN(c2ccc(N3CCC4(CCNC4)CC3)cc2)C(=O)N1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 7/20 0.54
DDB1 Q16531 6/20 0.54
USP2 O75604 5/20 0.47
CYP2D6 P10635 5/20 0.47
SLC6A2 P23975 1/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
ALDH1A1 P00352 5/20 0.41
CYP1A2 P05177 4/20 0.41
CYP3A4 P08684 3/20 0.41
TP53 P04637 3/20 0.40
MAPK1 P28482 3/20 0.40
HSD17B10 Q99714 3/20 0.40
HPGD P15428 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP2C19 P33261 1/20 0.40
CYP11B1 P15538 1/20 0.39
TSHR P16473 3/20 0.37
USP28 Q96RU2 1/20 0.37
KCNH2 Q12809 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30768600 0.92 DDB1 (0.51) CRBNDDB1USP2CYP2D6ALDH1A1
SCHEMBL30769340 0.92 DDB1 (0.51) CRBNDDB1USP2CYP2D6ALDH1A1
SCHEMBL31306915 0.83 CRBN (0.56) CRBNDDB1USP2CYP2D6ALDH1A1
SCHEMBL30769043 0.83 DDB1 (0.48) CRBNDDB1USP2CYP2D6SLC6A2
Hydrochloric Acid SCHEMBL30769009 0.82 DDB1 (0.47) CRBNDDB1USP2CYP2D6SLC6A2
SCHEMBL22119794 0.81 CRBN (0.65) CRBNDDB1USP2ALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL22119617 0.80 CRBN (0.63) CRBNDDB1USP2ALDH1A1HSD17B10
SCHEMBL25263523 0.79 CRBN (0.48) CRBNDDB1USP2CYP2D6ALDH1A1
SCHEMBL25632147 0.78 DDB1 (0.47) CRBNDDB1USP2CYP2D6ALDH1A1
Hydrochloric Acid SCHEMBL30525346 0.77 DDB1 (0.46) CRBNDDB1USP2CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2025-12-25 US disclosed
EP-4543871-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-04-30 EP disclosed
WO-2024006781-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-01-04 WO disclosed
WO-2024006776-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388565-A1 ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF ESRRA, ESRRB, ESR2 CRBN 488/4885DDB1 2204/4885USP2 782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.